BPC-157 (gut use)

BPC-157 is derived from a sequence within human gastric juice protein BPC and is stable in gastric acid, which is why oral dosing is plausible for luminal targets at all. In rodents it activates the VEGFR2-Akt-eNOS axis, increases nitric oxide availability, and accelerates granulation tissue formation and epithelial restitution in the stomach, small bowel and colon. It also appears to counteract NSAID and alcohol-induced mucosal injury, restore gut-brain vagal signalling, and improve intestinal anastomosis and fistula healing in rats. Every one of these mechanisms is established in animals; none has been confirmed in a completed human efficacy trial.

Targets: VEGFR2, Nitric oxide / eNOS pathway, Growth hormone receptor upregulation, NF-kB signalling

• · Reconstituted peptide is swallowed directly, or capsules are used. This is the route that makes mechanistic sense for gastritis, ulcers and IBD-type complaints, since the peptide survives gastric acid.
• · Most anecdotal protocols land at 250-500 mcg per dose, 250-1000 mcg per day total. There is no dose-ranging human data behind any of these numbers.

Work out your exact syringe units →

• commonInjection-site irritation or a small welt— Transient, resolves within a day.
• commonUnknown long-term effects— There is no human safety database at all beyond one small phase 1/2 IBD study. This is the honest headline risk.
• uncommonTransient nausea or a heavy stomach feeling after oral dosing— Usually settles if taken with a small amount of water rather than dry.
• uncommonMild lightheadedness or flushing— Consistent with the nitric oxide mechanism.

• Active or recently treated malignancy — the compound is explicitly pro-angiogenic and that is the wrong signal to add to a tumour bed.
• Anyone unwilling to accept a compound with zero completed human efficacy trials.

• synergykpv-gut — The standard oral gut stack: BPC-157 for mucosal repair, KPV for NF-kB-driven inflammation.
• synergytb-500 — Commonly stacked for systemic soft-tissue repair, less relevant for purely luminal gut goals.
• cautionnsaids — Rodent data show BPC-157 protects against NSAID gut damage, which is exactly why some people use it to keep taking NSAIDs they should probably stop.

• · Track the actual gut endpoint objectively — stool frequency, pain scores, or repeat endoscopy if you had one to begin with.
• · If you have IBD, do not let symptomatic improvement substitute for calprotectin or CRP monitoring.

Not approved for human use in the US or EU. The FDA placed BPC-157 in Category 2 of the 503A compounding bulks list in 2023, effectively removing it from compounding pharmacies; it is sold as a research chemical and is banned by WADA.

• Sikiric et al., stable gastric pentadecapeptide BPC 157 and the gut-brain axis (review series) (review)
• PL-14736 phase 1/2 study in ulcerative colitis, Pliva (trial)
• FDA 503A Bulk Drug Substances Category 2 listing, 2023 (guideline)

The honest starting point is that no receptor for BPC-157 has ever been identified. Not a low-affinity one, not a candidate one — none. Every mechanism in the literature is a downstream change observed in rodent tissue after dosing, which is a different and much weaker class of evidence than a binding constant. What the rodent work consistently shows is upregulation of VEGFR2 expression with increased phosphorylation of Akt and eNOS, raising local nitric oxide. That axis plausibly explains the two things BPC-157 is most reliably reported to do in animals: accelerate granulation tissue formation and increase microvascular density at an injury site. In gut-specific models it also restores blood flow through injured mesenteric and portal vasculature, which is the most mechanistically interesting finding in the whole corpus — a lot of the ulcer and fistula healing may be a perfusion effect rather than a direct epithelial one. The second arm is inflammatory. BPC-157 reduces NF-kB-driven cytokine output and myeloperoxidase in colitis models, and counteracts the mucosal injury caused by NSAIDs and ethanol. The gut-brain claims come from work showing it modulates dopaminergic and serotonergic systems and vagal signalling in rats. The structural problem with all of this is that the overwhelming majority comes from one research group in Zagreb, publishing over three decades. That does not make the findings wrong. It does mean independent replication is thin enough that you should treat the mechanism as a hypothesis with an unusually large amount of supporting rodent data rather than as established biology.

The most common real failure is not a side effect, it is a misattribution. Gut symptoms fluctuate enormously on their own. People start BPC-157 during a bad patch, regress to the mean over two weeks, and conclude the peptide healed them. Then they keep taking it for a year, having never established a baseline or an objective endpoint. The second failure is masking. Somebody with an undiagnosed ulcer, coeliac disease, IBD or a malignancy feels better for six weeks, delays the endoscopy, and presents later with something worse. Peptides that reduce inflammation without treating the cause are very good at buying that delay. The third is product quality. This is an unregulated grey market. The failure modes are underfilled vials, the acetate salt sold as the arginate, endotoxin contamination causing injection-site reactions that get blamed on the peptide, and outright substitution. If you have never had a batch tested, you do not know what you have been taking. The fourth, specific to oral dosing: people reconstitute with bacteriostatic water and then swallow it, which is fine, but store the reconstituted vial for months at room temperature because it is 'only going in my stomach anyway'. It degrades on the same timeline regardless of where you eventually put it.

1. 250 mcgWeek 1 — 250 mcg once daily. This is community practice, not a validated schedule — there is no human dose-ranging study of any kind. The only reason to start low is to find out whether you get the nitric-oxide flushing or the oral nausea before you commit to twice-daily dosing.
2. 500 mcgWeeks 2-8 — 250 mcg twice daily, or 500 mcg once daily. This is where the overwhelming majority of protocols sit. Going higher is not supported by anything; the rodent effective doses translate all over the map depending on which allometric assumption you use.
3. —Week 8 onward — Stop and reassess against your objective marker. If calprotectin, haemoglobin or your endoscopic finding has not moved in eight weeks, another eight weeks will not fix it. Continuous multi-month use is common in the gut community and has zero safety data behind it.

• VEGFR2 (KDR) — No binding constant has ever been published. BPC-157 has never been shown to bind VEGFR2 directly.

  Increased VEGFR2 expression and downstream Akt/eNOS phosphorylation in rodent injured tissue, driving angiogenesis and granulation. Blocking VEGFR2 abolishes several of BPC-157's healing effects in rats, which is the strongest functional evidence that the axis is load-bearing.

• eNOS / nitric oxide pathway — Not a binding target — a pathway effect.

  Raises nitric oxide availability. This is the likely explanation for the mild flushing and lightheadedness some users report, and for the vascular recruitment seen in rat mesenteric injury models.

• NF-kB signalling — No binding data.

  Reduced nuclear translocation and downstream IL-6 and TNF-alpha output in rodent colitis. Contributes to the anti-inflammatory half of the gut claim.

• Growth hormone receptor — No binding data.

  Increased GHR expression reported in cultured rat tendon fibroblasts. Frequently cited as a systemic mechanism; it is a single-tissue in-vitro observation and should not be read as a systemic GH effect.

• NCT02637284 — Phase I pilot study of PCO-02 (active ingredient BPC-157) in healthy volunteers Phase 1 · n=42 · 2015

  Adverse events, with pharmacokinetics of BPC-157 as a stated objective. Sponsor PharmaCotherapia d.o.o., intervention listed as Bepecin. Registered with a start date of October 2015; ClinicalTrials.gov status remains Unknown and no results have been posted.

• NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair Phase 2 · n=120 · 2026

  Muscle strain repair in acute hamstring injury. Recruiting as of this writing. Not a gut trial, but it is the first properly registered phase 2 of BPC-157 in humans and is worth watching because it will produce the first real safety dataset.

• PL-14736 phase 1/2 in ulcerative colitis (Pliva) Phase 1/2

  Reported as a safety and efficacy study of intrarectal PL-14736 in ulcerative colitis. Searches of PubMed and ClinicalTrials.gov in this session failed to surface a registration record or a peer-reviewed results publication. This trial is cited constantly in BPC-157 marketing and I could not verify it. Treat it as unconfirmed.

Subjective gut symptom change is typically reported at 7-14 days. That window is short enough to be indistinguishable from natural fluctuation, which is why the objective marker matters. Rodent mucosal healing endpoints — ulcer area, anastomotic strength, fistula closure — run 2-4 weeks. If you are going to give this a fair trial, eight weeks with a baseline and a repeat calprotectin is the minimum that produces information rather than a feeling.

The default oral gut stack is BPC-157 plus KPV, and the logic is coherent even if the evidence is not: BPC-157 for the repair and perfusion side, KPV for the NF-kB inflammatory side, both taken on an empty stomach so they reach mucosa rather than sitting in a food bolus. Adding colostrum is the third layer people reach for, and it is the only member of that trio with human randomised data. If you are going to run three things, run colostrum first for four weeks alone so you know what it does by itself. Do not stack BPC-157 with anything else pro-angiogenic if you have any oncological history. The compound's entire claimed mechanism is growth factor signalling in a tissue bed, and there is no version of that story where it selectively avoids a tumour. The combination that deserves a hard look is BPC-157 with continued NSAID use. Rodent data genuinely show protection against NSAID gut injury, and that finding is being used in practice as a licence to keep taking the NSAID that caused the problem. You are adding an unproven peptide to preserve a proven irritant.

Against everything else in this class, BPC-157 is the compound with the largest gap between confidence and evidence. Teduglutide and linaclotide have label-grade phase 3 data. Larazotide ran a real phase 3 and failed. Colostrum has small but genuine randomised human permeability trials. BPC-157 has three decades of rodent work from largely one laboratory, one unverifiable phase 1/2 in ulcerative colitis, and one registered phase 1 that never reported. It is not that the compound has been shown not to work — it is that it has never been properly tested in a human being with a gut disease. If your actual problem is IBS-C, linaclotide or plecanatide will outperform it and you can get them prescribed. If your problem is coeliac symptoms on a gluten-free diet, larazotide already failed that trial and BPC-157 has not attempted it. If your problem is genuine barrier permeability, colostrum has the only human data. BPC-157's remaining honest niche is NSAID and alcohol-related gastric injury, where the animal data are strongest and no good alternative peptide exists.

$25–$90/month. Typical grey-market pricing for 5 mg and 10 mg vials at 250-500 mcg per day; roughly three 5 mg vials a month at the higher dose. Prices vary by a factor of three between vendors and cheaper is frequently a signal about purity rather than efficiency. Third-party testing adds roughly $60-120 per batch and is the single best use of money in this category. These are observed market ranges, not verified figures.

• ?No human pharmacokinetic data exist. Every PK field here is null because nobody has measured it, not because I could not find it.
• ?The PL-14736 phase 1/2 ulcerative colitis trial could not be verified in this session — no ClinicalTrials.gov registration and no indexed publication was found. It is cited universally and I could not confirm it exists in a reportable form.
• ?The half-life figure of 'minutes' is a rodent plasma observation repeated across reviews; I did not resolve a primary source giving a numeric human or rodent t-half.
• ?Whether BPC-157 crosses the blood-brain barrier is genuinely unknown. Rodent CNS effects after peripheral dosing are reported, but that is consistent with either penetration or vagal signalling, and no distribution study distinguishes them.
• ?The claim that the arginate salt is meaningfully more stable in solution than the acetate is widely repeated and mechanistically plausible; I did not find a published stability comparison.
• ?Molecular weight of 1419.5 Da is confirmed against PubChem for the free base. Vendor material is usually a trifluoroacetate or acetate salt, so the mass in a vial is not the mass on the label.
• ?The FDA 503A Category 2 listing referenced in the Core record is widely reported but the FDA pages I attempted to fetch returned 404 in this session, so it is not cited here as verified.

• Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function Sikiric P, et al., Pharmaceuticals (Basel), 2023 · PMID 37242459

  The most complete recent statement of the gut-brain case from the group that generated essentially all of it. Read it as a well-organised hypothesis document rather than as a neutral systematic review.

• New studies with stable gastric pentadecapeptide protecting gastrointestinal tract Sikiric P, et al., Inflammopharmacology, 2024 · PMID 38980576

  Current summary of the GI protection literature, including the NSAID and alcohol injury models that are the strongest part of the animal case.

• Pentadecapeptide BPC 157 and the central nervous system Vukojevic J, et al., Neural Regeneration Research, 2022 · PMID 34380875

  Relevant to the gut-brain claims specifically, and to the unresolved question of whether anything reaches the CNS.

• PubChem CID 9941957 — BPC-157, C62H98N16O22, MW 1419.5, CAS 137525-51-0 PubChem, National Library of Medicine

  Sequence and molecular weight verification. Confirms GEPPPGKPADDAGLV and 1419.5 Da, and lists Bepecin as a synonym — the trade name used in the registered phase 1 study.